Mark Lappe - May 29, 2024 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INXB)

Role: Chief Executive Officer, Director
Signature: /s/ Kelly D. Deck, Chief Financial Officer of Inhibrx Biosciences, Inc., attorney-in-fact
Stock symbol: INXB
Transactions as of: May 29, 2024
Transactions value $: $0
Form type: 4
Date filed: 5/30/2024, 06:10 PM
Previous filing: May 24, 2024
Next filing: May 30, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INXB	Common Stock	Award		+622K			622K	May 29, 2024	By the Lappe Family Trust	F1, F2
transaction	INXB	Common Stock	Award		+125K			125K	May 29, 2024	By trust	F1, F3
transaction	INXB	Common Stock	Award		+14.9K			14.9K	May 29, 2024	The Mark Paul Lappe Roth IRA	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INXB	Stock Option (right to buy)	Award	$0	+300K		$0.00	300K	May 30, 2024	Common Stock	300K	$15.86	Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.
F2	These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.
F3	These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.
F4	This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.
F5	Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.